Selected Value Therapeutics Acquires China Rights to Cancer Drug

Selected Value Therapeutics will acquire the China rights to a cancer drug being developed by US-based EntreMed. The drug, ENMD-2076, has announced efficacy in a Phase II trial conducted among ovarian cancer patients with platinum-drug resistance, a notoriously difficult population without many treatment options. To gain China rights for the drug, Selected Value is exercising an option it acquired in late 2010, when it invested $5.1 million in a private placement of EntreMed units. More details.... Stock Symbol: (NSDQ: ENMD)     Share this with colleagues: